Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at Okayama University discuss research in cancer vaccines
September 23rd, 2008
New investigation results, 'Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient,' are detailed in a study published in Cancer Immunology, Immunotherapy. According to a study from Okayama, Japan, "NY-ESO-1 is a cancer/testis antigen highly immunogenic in cancer patients. Cholesterol-bearing hydrophobized pullulan (CHP) is a nanoparticle-forming antigen-delivery vehicle and CHP complexed with NY-ESO-1 protein (CHP-NY-ESO-1) efficiently activates CD4 and CD8 T cells in vitro." "In this study we report on a 50-year-old male melanoma patient with multiple skin and organ metastases (T4N3M1c) who was...
Source: Cancer Weekly (2008-09-23)
|
